Rheumatology 2002; 41: 22-26
© 2002 British Society for Rheumatology
Original Papers |
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality
Centre for Rheumatology, Department of Medicine, University College Hospital, London W1P 9PG, UK
Objective. To assess the long-term outcome of a cohort of 46 patients with idiopathic myositis by assessing both health status, as measured by the SF-36, and cumulative survival probability over a 20-yr follow-up period at a single rheumatology centre.
Methods and results. Forty-six patients under long-term follow-up from 1978 to 1999 were identified from our database. All patients fulfilled three out of four of the Bohan and Peter criteria for myositis. We excluded those with malignancy-associated disease and those with inclusion body myositis. Twenty-three patients (50%) had adult-onset polymyositis, 14 (30.4%) had adult-onset dermatomyositis, one had childhood-onset dermatomyositis and eight (17.4%) had an overlap syndrome (associated with either systemic lupus erythematosus or rheumatoid arthritis). During the course of the disease, seven patients (15.2%) went into full remission, eight (17.4%) had monophasic illness, nine (19.6%) had a relapsing–remitting course, 16 (34.8%) had chronic progressive illness and six (13.04%) died. All patients had significantly lower SF-36 scores in all aspects of health compared with the general population (P
0.001). Patients with chronic progressive illness had significantly greater bodily pain (P0.05, t-test) than those with a relapsing–remitting illness, but did not differ in other aspects of health. There was no significant difference in the scores in the different domains of the SF-36 between the patients with active disease and those with inactive disease (0.05<P<0.1). Six of the 46 patients died. Cumulative survival probability was calculated. The five-year survival rate was 95% and the 10-yr survival rate 83.8%.
Conclusion. Patients with myositis report significantly poorer health compared with the general population. Health status and disease activity are important outcome measures in the assessment of patients with myositis.
KEY WORDS: Idiopathic myositis, Morbidity, SF-36, Treatment, Mortality.
Correspondence to: S. M. Sultan, Department of Rheumatology, 4th Floor, Arthur Stanley House, 40–50 Tottenham Street, London W1P 9PG, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. O. Harris-Love, J. A. Shrader, D. Koziol, N. Pahlajani, M. Jain, M. Smith, H. L. Cintas, C. L. McGarvey, L. James-Newton, A. Pokrovnichka, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis Rheumatology, February 1, 2009; 48(2): 134 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-K. Somani, A. R. Swick, K. D. Cooper, and T. S. McCormick Severe Dermatomyositis Triggered by Interferon Beta-1a Therapy and Associated With Enhanced Type I Interferon Signaling Arch Dermatol, October 1, 2008; 144(10): 1341 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Tillie-Leblond, M Wislez, D Valeyre, B Crestani, A Rabbat, D Israel-Biet, M Humbert, L J Couderc, B Wallaert, and J Cadranel Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset Thorax, January 1, 2008; 63(1): 53 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Lundberg The heart in dermatomyositis and polymyositis Rheumatology, October 1, 2006; 45(suppl_4): iv18 - iv21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ponyi, G. Borgulya, T. Constantin, A. Vancsa, L. Gergely, and K. Danko Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis Rheumatology, January 1, 2005; 44(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Isenberg, E. Allen, V. Farewell, M. R. Ehrenstein, M. G. Hanna, I. E. Lundberg, C. Oddis, C. Pilkington, P. Plotz, D. Scott, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease Rheumatology, January 1, 2004; 43(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Haq and D A Isenberg Myositis and swollen knees: disease or treatment complication? Ann Rheum Dis, June 1, 2002; 61(6): 544 - 546. [Abstract] [Full Text] [PDF]
|
|